Alnylam Pharma (ALNY) Tops Q4 EPS by 49c; offers guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $286.41 +2.99%
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($0.77), $0.49 better than the analyst estimate of ($1.26). Revenue for the quarter came in at $346.29 million versus the consensus estimate of $436.08 million.
GUIDANCE:
Alnylam Pharma sees FY2024 revenue of $1400-1500 million, versus the consensus of $1770 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
- Accenture downgraded by TD Cowen on AI concerns
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
